Kepler Vision vs Owkin

Owkin has a disclosed valuation of $1B, while Kepler Vision's valuation is not publicly available, making a direct size comparison difficult. Owkin employs 450 people.

Owkin has raised $334M in disclosed funding across 3 known rounds. Kepler Vision's funding history is not publicly available.

Owkin holds the higher Awaira Score at 69/100, compared to Kepler Vision's 30/100. The Awaira Score is a composite metric factoring in valuation, funding, stage, team size, and market presence — a 39-point gap that reflects meaningful differences in scale or traction.

Kepler Vision was founded by Harro Stokman in 2017. Owkin was founded by Thomas Clozel in 2016. Visit each company's profile on Awaira for a full founder biography.

Kepler Vision: Kepler Vision Technologies develops AI fall detection and activity recognition software for elderly care environments, using computer vision models that process video from ceiling-mounted cameras in care facilities to detect falls, assess resident activity patterns, and alert care staff to incidents requiring immediate response. The Amsterdam company platform is designed to operate without wearables or pressure sensors, relying entirely on camera-based analysis to provide unobtrusive monitoring.\n\nThe company is early stage with initial funding from Dutch innovation programmes and care sector partners. Kepler Vision has piloted its Night Nurse product in Dutch residential care facilities, where staff shortages create demand for AI monitoring tools that can maintain safety oversight overnight when staffing ratios are lowest. The platform is designed to comply with European privacy regulations governing personal data processing in care environments, using on-device processing to avoid transmitting identifiable video to cloud services.\n\nKepler Vision operates in the AI elder care market alongside CarePredict, SafelyYou, and camera-based monitoring startups targeting the intersection of computer vision and residential care. The European elder care AI market faces distinct regulatory challenges compared to the US, with GDPR-compliant video monitoring in care facilities requiring explicit consent frameworks and data minimisation approaches. The Netherlands position as a leader in healthcare technology innovation and its advanced residential care infrastructure make it a relevant test market for technology that addresses the growing caregiver shortage across European social care systems. Owkin: Owkin is a French AI healthcare company founded in 2016 that develops federated learning and privacy-preserving machine learning technologies for drug discovery and clinical research. The company operates a distributed AI platform enabling pharmaceutical companies, biotech firms, and research institutions to collaborate on data analysis without sharing sensitive patient information or proprietary datasets. Owkin's core technology utilizes federated learning, allowing multiple parties to train machine learning models collectively while maintaining data privacy and regulatory compliance, particularly under GDPR and HIPAA frameworks. The company has raised $334 million in total funding and achieved a $1.0 billion valuation, positioning it as a significant player in the intersection of AI, privacy-tech, and healthcare. Owkin operates in the Series B stage and serves pharmaceutical companies seeking to accelerate drug development through collaborative AI while preserving data confidentiality. The platform addresses a critical challenge in healthcare AI: enabling large-scale machine learning without centralizing sensitive medical data. Owkin's approach contrasts with traditional cloud-based analytics solutions by maintaining data sovereignty at source institutions. The company has established partnerships across the pharmaceutical and research sectors, though specific customer names and financial metrics remain Not disclosed. Its growth trajectory reflects expanding demand for privacy-preserving AI solutions in highly regulated healthcare markets. Owkin combines federated learning with healthcare applications, enabling collaborative AI research without compromising data privacy or regulatory compliance across distributed pharmaceutical ecosystems.

Owkin was founded first in 2016, giving it 1 year of additional market experience. Kepler Vision was founded later in 2017. In AI, even a year or two of head start can translate into significantly more training data, customer relationships, and institutional knowledge.

Kepler Vision has approximately 1-50 employees, while Owkin has approximately 450. A larger team often signals higher revenue or venture backing, but in AI, smaller teams are increasingly capable of building at scale.

Yes, Kepler Vision and Owkin are direct competitors — both operate in the AI Healthcare space and likely target overlapping customer segments. This comparison is especially relevant for buyers evaluating both platforms.